# Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)

> Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) trades at $30.91 (+2.32%) as of 7:30:04 PM EST on Nov 10, 2026, +12.48% over the past month. Market cap is $3.88B, with 10.5 days to cover in short interest.

Canonical: https://massive.com/quote/amlx
Data as of: 2026-11-11T00:30:04.761Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$30.91** +0.70 (+2.32%)
As of 7:30:04 PM EST on Nov 10, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +2.32% |
| 1W | +5.86% |
| 1M | +12.48% |
| YTD | +155.88% |
| 1Y | +150.69% |
| 52-wk range | $10.83 – $41.14 |

From daily closes through Nov 10, 2026.

## Key statistics

Today's trading snapshot for AMLX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $29.76 – $31.22 |
| Open | $29.94 |
| Prev close | $30.21 |
| Volume | 1.42M |
| Market cap | $3.88B |
| Shares out | 111.42M |

## Valuation and profitability ratios

Valuation and profitability ratios for Amylyx Pharmaceuticals, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 5.15 |
| P/FCF | — |
| ROE | -21.6% |
| ROA | -20.7% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 9, 2026

## Insider trading

[Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) insider trading](https://massive.com/quote/amlx/insider-trading.md): open-market Form 4 buys and sells by Amylyx Pharmaceuticals, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Amylyx Pharmaceuticals, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 5, 2026, Amylyx Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.”
- Sep 8, 2026 · Significant contract award
  “On September 8, 2026, Amylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc. pursuant to which Bachem will manufacture and supply the Company's long-term supply requirements of avexitide drug substance for commercial use, if approved.”
- Aug 20, 2026 · Public offering
  “On August 19, 2026, Amylyx Pharmaceuticals, Inc. entered into an underwriting agreement with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC, as representatives of the several underwriters named therein, relating to the issuance and sale of an aggregate of 14,090,000 shares of the Company's common stock at a price to the public of $35.50 per share.”
- Aug 18, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “LUCIDITY met the Food and Drug Administration (the "FDA")-agreed-upon primary endpoint demonstrating a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003). In addition, LUCIDITY met all secondary endpoints demonstrating consistent, highly statistically significant, and clinically meaningful reductions in Level 2 hypoglycemic events by self-monitoring of blood glucose ("SMBG"), Level 2 hypoglycemic events by continuous glucose monitoring ("CGM"), and Level 3 hypoglycemic events.”
- Aug 18, 2026 · Investor presentation
  “Selected slides from the investor presentation used during the conference call are attached as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference.”

## Dividend history and stock splits

Amylyx Pharmaceuticals, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

- $0.42 · ex-div Mar 28, 2018
- $0.36 · ex-div Dec 28, 2017
- $0.24 · ex-div Sep 28, 2017

### Splits

No recent splits.

## AMLX short interest

How heavily AMLX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 10.5 |
| Short interest | 12.82M |
| Avg volume | 1.22M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## AMLX news

The latest news and headlines about Amylyx Pharmaceuticals, Inc. Common Stock (AMLX).

- [Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?](https://www.fool.com/investing/2026/09/01/is-glp-1-stock-amylyx-still-buy-after-skyrocketing/?source=iedfolrf0000001) · The Motley Fool · Sep 1, 2026 · positive sentiment
- [Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](https://www.globenewswire.com/news-release/2026/02/19/3240807/0/en/Global-Amyotrophic-Lateral-Sclerosis-Therapeutics-Market-Size-Share-Worth-USD-1964-Million-by-2035-at-11-5-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Foreca.html) · GlobeNewswire Inc. · Feb 19, 2026 · positive sentiment
- [Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain \| DelveInsight](https://www.globenewswire.com/news-release/2025/08/28/3141021/0/en/Antisense-Oligonucleotide-Therapeutics-Clinical-Trial-Pipeline-Appears-Robust-With-70-Key-Pharma-Companies-Actively-Working-in-the-Domain-DelveInsight.html) · GlobeNewswire Inc. · Aug 28, 2025 · positive sentiment
- [AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm](https://www.globenewswire.com/news-release/2025/07/14/3115251/0/en/AMYLYX-ALERT-Bragar-Eagel-Squire-P-C-is-Investigating-Amylyx-Pharmaceuticals-Inc-on-Behalf-of-Long-Term-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html) · GlobeNewswire Inc. · Jul 14, 2025 · negative sentiment
- [AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm](https://www.globenewswire.com/news-release/2025/07/08/3111414/0/en/AMYLYX-ALERT-Bragar-Eagel-Squire-P-C-is-Investigating-Amylyx-Pharmaceuticals-Inc-on-Behalf-of-Long-Term-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html) · GlobeNewswire Inc. · Jul 7, 2025 · negative sentiment

## About Amylyx Pharmaceuticals, Inc. Common Stock

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 136 |
| Listed | Jan 7, 2022 |

[Company website](https://www.amylyx.com)

## FAQ

### What is the Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) stock price today?

Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is trading at $30.91 (+2.32% on the day) as of 7:30:04 PM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Amylyx Pharmaceuticals, Inc. Common Stock?

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases.

### What is the short interest in AMLX?

As of Oct 30, 2026, AMLX has 12.82M shares short and 10.5 days to cover.

### Does Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) pay a dividend?

Yes. Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)'s most recent dividend was $0.42 per share, with an ex-dividend date of Mar 28, 2018. Full AMLX dividend history is available from the Massive API.

### What exchange is AMLX listed on?

Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time AMLX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=AMLX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) insider trading](https://massive.com/quote/amlx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms